

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>020884-000008</b>
<b>Applicant(s):</b>	)	<b>Examiner:</b>	<b>Zinna</b>
<b>Juan Carlos Lacal Sanjuan, et al.</b>	)		<b>Northington</b>
	)		<b>Davis</b>
<b>Application No.:</b>	)	<b>Art Unit:</b>	<b>1625</b>
<b>10/597,095</b>	)		
<b>U.S. Filing Date:</b>	)	<b>Conf. No.:</b>	<b>5976</b>
<b>September 29, 2006</b>	)		
<b>Title:</b>	)	<b>Customer No.:</b>	<b>24239</b>
<b>DERIVATIVES OF PYRIDINE AND</b>	)		
<b>QUINOLINE</b>	)		

---

**RESPONSE TO THE MAY 6, 2009 RESTRICTION REQUIREMENT IN U.S. PATENT  
APPLICATION NO. 10/597,095**

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This responds to the May 6, 2009 Restriction Requirement in the subject patent application.